First patient enrolled in merit medical's motion study

South jordan, utah, jan. 16, 2024 (globe newswire) -- merit medical systems, inc. (nasdaq: mmsi), a leading global manufacturer and marketer of healthcare technology, today announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (gae) using embosphere® microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis (motion) study.
MMSI Ratings Summary
MMSI Quant Ranking